When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose give, and 2) for how long? The issue optimal duration has been subject several randomized trials is especially pertinent in context a global BCG shortage. Despite this, there appears uncertainty as whether or may c...
